Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of topical P144 cream in cutaneous fibrosis of systemic sclerosis
2008-001265-28Phase 2Active
- Sponsor
- ISDIN
- Start
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitertide in systemic sclerosis (SSc), sponsored by ISDIN. Primary endpoint: Long-term safety of Digna P144 cream. Started Apr 2008; status: active.
02
Drugs
disitertide
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2008-001265-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001265-28.